Mereo BioPharma’s setrusumab misses primary endpoints in Phase 3 bone disease trials
Mereo BioPharma (NASDAQ:MREO) said Phase 3 trials of setrusumab (UX143) in osteogenesis imperfecta failed to meet their primary endpoints, dealing a setback to the late-stage program as the company moves to cut spending and reassess priorities.









-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)